Quick Answer
Dermata Therapeutics, Inc. reported Net Income Loss of -$7.56 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +38.5% in Net Income Loss from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.42 million | Q2 2020: -$821.6 thousand | Q3 2020: -$597.4 thousand | Q4 2020: -$396.3 thousand | Q1 2021: -$2.30 million | Q2 2021: -$1.33 million | Q3 2021: -$1.71 million | Q1 2022: -$2.79 million | Q2 2022: -$2.73 million | Q3 2022: -$2.42 million | Q1 2023: -$2.24 million | Q2 2023: -$1.70 million | Q3 2023: -$1.72 million | Q1 2024: -$3.13 million | Q2 2024: -$2.83 million | Q3 2024: -$3.17 million | Q1 2025: -$2.30 million | Q2 2025: -$1.70 million | Q3 2025: -$1.69 million.
- Over the full 6 years of available data (2020 to 2025), Dermata Therapeutics, Inc.'s Net Income Loss has declined by 133.5%.
- Historical annual values: Fiscal year 2025: -$7.56 million | Fiscal year 2024: -$12.29 million | Fiscal year 2023: -$7.79 million | Fiscal year 2022: -$9.61 million | Fiscal year 2021: -$7.90 million | Fiscal year 2020: -$3.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: